Sudhakar Akul Yakkanti
Many endogenous anti-cancer molecules which are released from extracellular matrix were identified as angioinhibitors of tumor growth. Many of these endogenous anti-cancer molecules bind to the cell surface integrins and transduce the angioinhibitory signaling. Two of such endogenous molecules derived from the C-terminal non-collagenous domain of type IV collagen alpha 1 and 3 chains were identified as angioinhibitors, but their mediated signaling is not yet known. Our findings suggests that these molecules binding to integrins and inhibiting different signaling that leading to inhibition of in-vitro and in-vivo tumor angiogenesis and tumor growth.
Sudhakar Akul Yakkanti is the founder Director of Cell Signaling, Retinal and Tumor Angiogenesis Laboratory at Boys Town National Research Hospital, Associate Professor at University of Nebraska Medical Center, Omaha, NE, USA. He did his postdoctoral training at Harvard Medical School, Boston, MA, USA (2003). He received President?s fellowship (1992), GATE (1996) and CSIR (2007-2000) fellowships from Government of India. He received Mahindra & Mahindra Educational Award (2000) and Young Clinical Scientist Awards from FAMRI in 2007 and 2010. He also received Bio-Bio Young Scientist Award from OMICS publishing group; Michael A. O?Connor Young Investigator Award; RO1 grant Award from NIH/NCI and Research Scholar Grant from ACS (2010-funding on ?Pay-if category). He is serving as AIBS/NIH-RO1 Grant reviewer for DT study section. He has published more than 40 research articles in several top journals including Science, Cancer Cell, JCI, Blood, PNAS, Gastroenterology, Cancer Research, JBC etc. He is serving as an Editor-in-Chief, Executive Editor, Editor and Editorial board member of reputed journals and is serving as a reviewer for more than 26 scientific journals including JCI, Blood, Circulation, Circulation Research, Cancer research, Clinical Cancer research etc. He was honored by giving a position as Keynote Speaker, Chairman, Co-chairman and organizing committee member for several international conferences.
Cancer Science & Therapy received 3358 citations as per Google Scholar report